Ubs Asset Management Americas Inc Madrigal Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 22,356 shares of MDGL stock, worth $7.34 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,356
Previous 24,609
9.16%
Holding current value
$7.34 Million
Previous $6.89 Million
31.19%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding MDGL
# of Institutions
295Shares Held
21.9MCall Options Held
819KPut Options Held
644K-
Janus Henderson Group PLC London, X02.48MShares$813 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$670 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$666 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$654 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$648 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.61B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...